Femasys up on completing enrollment for birth control solution trial

Femasys

06/10/2022 15:41

** Shares of Femasys Inc  FEMY.O  gain ~5% to $1.21
    ** Company says it has completed enrollment for a mid-stage
study of its nonsurgical solution, FemBloc, in development for
permanent birth control  urn:newsml:reuters.com:*:nGNX71X8kK
    ** FemBloc method seeks to prevent pregnancy by causing
fallopian tubes to close over time using a liquid, which is put
through a thin plastic tube placed into uterus
    ** Including session's gain, stock down 69% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))